Expert Interview
A look at Amgen's Phase 3 data for UPLIZNA (inebilizumab-cdon), an anti-CD19 mAb, for patients with generalized Myasthenia Gravis
Ticker(s): AMGNInstitution: Haukeland Univ. Hospital
- Professor in neurology at University of Bergen and senior consultant at Department of Neurology at Haukeland University Hospital
- Treats 50 patients with myasthenia gravis
- Areas of interest innclude Epilepsy, myasthenia gravis, neuroimmunology, and mother-child health in neurology.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
